Оцінка безпеки застосування левофлоксацину при лікуванні хворих на туберкульоз органів дихання

Abstract

The aim of the study – to assess safety of levofloxacin use in the treatment of patients with respiratory tuberculosis in the Kharkiv region for 2025. The safety assessment of pharmacotherapy by levofloxacin was carried out using the method ofspontaneous reports, which is widely used in pharmacovigilance. There were analyzed the report ca on adverse reactions received from phthisiatric healthcare institutions of the Kharkiv region in 2025. During the conducted pharmacovigilance study, it was found that in the Kharkiv region in 2025, 32 cards-reports on adverse reactions were registered when using levofloxacin (tablets, 500 mg) for the treatment of respiratory tuberculosis. Adverse reactions developed in young and middle-aged men. 53 adverse reactions were registered in the report cards, among which the majority of patients' complaints were related to the gastrointestinal tract – 28.3% of cases; musculoskeletal system and skin – 20.8% of cases each; nervous system – 17.0% of cases; immune system – 11.3% of cases. All registered adverse reactions are non-serious and predictable. Thus, safety assessment showed that the treatment of respiratory tuberculosis with levofloxacin is relatively safe, as no serious and unpredictable adverse reactions were registered.